Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cancer Stem Cells Linked to Drug Resistance

April 21, 2014 10:59 am | News | Comments

Researchers have discovered a biomarker called CD61 on the surface of drug-resistant tumors that appears responsible for inducing tumor metastasis by enhancing the stem cell-like properties of cancer cells. Read more...          


'Chaperone' Compounds Offer New Approach to Alzheimer’s Treatment

April 21, 2014 10:53 am | News | Comments

A team of researchers has devised a wholly new approach to the treatment of Alzheimer’s disease involving the so-called retromer protein complex. Read more...                           


Biogen in License Agreement with Amunix for XTENylated Factor VIII

April 21, 2014 10:42 am | News | Comments

Amunix Operating Inc. announced that Biogen Idec has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties. Read more...


Daiichi Sankyo Names New Executive Appointment

April 21, 2014 10:21 am | News | Comments

Daiichi Sankyo Inc. announced that Ken Keller will join the company as president of its commercial operations in the United States starting May 1, 2014. In his role, Keller will be responsible for leading marketing, sales, medical affairs and supply chain operations. Read more...


$14M Awarded in Suit Linking Yasmin, Stroke

April 21, 2014 10:01 am | News | Comments

A jury has awarded $14 million to a suburban Chicago woman who sued her doctor over a debilitating stroke she suffered after taking Bayer's birth control drug Yasmin. Read more...                 


Court Declines to Block Ruling in Teva Patent Case

April 21, 2014 8:30 am | by Sam Hananel | News | Comments

Supreme Court Chief Justice John Roberts on Friday declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals next month. Read more...         


Breaking News: Cubist Recalls Cubicin Lot

April 18, 2014 2:02 pm | News | Comments

Cubist Pharmaceuticals Inc. announced it is voluntarily recalling one lot of Cubicin (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles. Read more...


Top French Advisor Resigns Amid Drug Industry Scandal

April 18, 2014 1:06 pm | News | Comments

Aquilino Morelle, the French president's top adviser, resigned Friday following allegations of a past conflict of interest, striking a new blow to the already unpopular Francois Hollande, sought to distance himself from the new scandal. Read more...


Washington University Launches Immunology Center

April 18, 2014 12:54 pm | by Michael Purdy | News | Comments

A new center at Washington University School of Medicine in St. Louis - The Center for Human Immunology and Immunotherapy Programs (CHiiPs)  -  will help scientists use the power of the immune system to fight infections and cancers. Read more...


New Pain Relief Targets Could Benefit Cancer Patients

April 18, 2014 12:36 pm | News | Comments

When researching how pain occurs in nerves in the periphery of the body, BBSRC-funded researchers at King's College London have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. Read more...


Phase 1/2 Results Positive for Cancer Drug

April 18, 2014 12:20 pm | News | Comments

XBiotech is announcing that results from its Phase 1/2 oncology study conducted at MD Anderson Cancer Center in Houston, TX were published in Lancet Oncology, which describes the outcome in 52 advanced cancer patients treated with Xilonix, XBiotech’s anti-tumor therapy. Read more...


Ivabradine Fast Tracked for Chronic HF

April 18, 2014 12:13 pm | News | Comments

The U.S. Food and Drug Administration (FDA) has granted fast track designation for investigational ivabradine - an oral drug that inhibits the If current (“funny” current) in the sinoatrial node, the body’s cardiac pacemaker - for patients with chronic heart failure (HF). Read more...


FDA Approves Arzerra for Chronic Lymphocytic Leukemia

April 18, 2014 12:03 pm | News | Comments

GlaxoSmithKline and Genmab announced that the FDA has approved a supplemental BLA for the use of Arzerra, a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia. Read more...


Anti-Seizure Drug Could Reduce Alcohol Consumption

April 18, 2014 10:34 am | News | Comments

Researchers have discovered that the anti-seizure drug ezogabine, reduced alcohol consumption in an experimental model. The findings may lead to more effective treatments for alcoholism. Read more...               


Actavis to Acquire New Products from Akorn

April 18, 2014 10:19 am | News | Comments

Actavis plc announced that it has entered into agreements with Akorn Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. Read more...         



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.